Wholly owned by Tethra Biosciences; acquired in October 2025 from the Cyclacel chemistry estate. In active Phase 1/2 development across solid tumors and lymphoma; AML combination program planned for 2027.
Development across three tracks
plogosertib's protection derives from the Cyclacel patent families, acquired by Tethra in October 2025. Coverage spans composition of matter and methods of use across major jurisdictions. A patent-status summary is available to qualified parties under CDA.
Tethra is pursuing standard FDA development pathways for plogosertib across its indication tracks. Designations, trial registrations, and protocol details will be disclosed through official regulatory channels.
Trials
Active and planned trials will be linked here with ClinicalTrials.gov identifiers as records are updated.
Contact us